Control programs for strongyloidiasis in areas of high endemicity: an economic analysis of different approaches

Table 4 Estimates of number of adverted infections and deaths and costs to avert one death following the different strategies, at the 1 and 10-year horizons

Strategy Horizon	Averted deaths, Number of individuals		Delta costs, in USD		Cost to avert one death, in USD		Averted infections, Number of individuals
Strategy Horizon	B vs A	C vs A	B vs A	C vs A	B vs A	C vs A	B vs A	C vs A
Prevalence 1*
1 year	82	22	269 750	29 750	3299	1346	31 820	8600
10 years	909	274	2 635 565	236 724	2901	863	353 531	106 768
Prevalence 2**
1 year	164	44	269.750	29 750	1649	673	63 640	17 200
10 years	1814	548	2 634 380	236 698	1452	432	705 982	213 392
Prevalence 3 (base scenario)***
1 year	245	66	269 750	29 750	1100	449	95 460	25 800
10 years	2717	822	2 633 195	236 671	969	288	1 057 356	319 871
Prevalence 4****
1 year	327	88	269 750	29 750	825	337	127 280	34 400
10 years	3618	1095	2 632 010	236 645	728	216	1 407 654	426 207

USD United States Dollars, A no treatment, B PC targeting SAC and adults, C PC targeting SAC, PC preventive chemotherapy, SAC School-age children
*Prevalence 1: 5% in school aged children and 9% in adults; **prevalence 2: 10% in school aged children and 18% in adults; ***prevalence 3: 15% in school aged children and 27% in adults; ****prevalence 4: 20% in school aged children and 36% in adults

ISSN: 2049-9957